For
the quarter ending june 2022, standalone net sales (including other operating income) of RPG Life Sciences has increased 19.24% to Rs 128.93 crore compared to quarter ended june 2021.Operating profit margin has jumped from 21.22% to 21.59%, leading to 21.31% rise in operating profit to Rs 27.84 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 19.17% to 16.77%. Purchase of finished goods cost rose from 13.63% to 15.87%. Employee cost decreased from 21.67% to 21.36%. Other expenses fell from 24.46% to 24.04%. Other income up 197.56% to Rs 1.22 crore. PBIDT rose 24.40% to Rs 29.06 crore. Provision for interest fell 15.38% to Rs 0.11 crore.
PBDT rose 24.62% to Rs 28.95 crore. Provision for depreciation down 3.28% to Rs 3.83 crore.
Profit before tax grew 30.36% to Rs 25.12 crore. Provision for tax was expense of Rs 6.91 crore, compared to Rs 5.69 crore. Effective tax rate was 27.51% compared to 29.53%.
Profit after tax rose 34.09% to Rs 18.21 crore.
Promoters’ stake was 72.41% as of 30 June 2022 ,compared to 72.07% as of 30 June 2021 .
Full year results analysis
Net sales (including other operating income) of RPG Life Sciences has increased 13.11% to Rs 440.16 crore. Operating profit margin has jumped from 17.97% to 19.62%, leading to 23.49% rise in operating profit to Rs 86.36 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 21.76% to 18.94%. Purchase of finished goods cost rose from 12.78% to 16.95%. Employee cost decreased from 24.02% to 21.48%. Other expenses rose from 23.71% to 24.07%. Other income up 228.57% to Rs 2.99 crore. PBIDT rose 26.13% to Rs 89.35 crore. Provision for interest fell 34.18% to Rs 0.52 crore. Loan funds declined from Rs 2.02 crore as of 31 March 2021 to Rs 0.94 crore as of 31 March 2022. Inventories rose to Rs 82.99 crore as of 31 March 2022 from Rs 58.33 crore as of 31 March 2021. Sundry debtors were lower at Rs 32.99 crore as of 31 March 2022 compared to Rs 57.42 crore as of 31 March 2021. Cash and bank balance rose to Rs 70.26 crore as of 31 March 2022 from Rs 40.75 crore as of 31 March 2021.
PBDT rose 26.81% to Rs 88.83 crore. Provision for depreciation down 4.92% to Rs 15.66 crore. Fixed assets increased to Rs 100.09 crore as of 31 March 2022 from Rs 87.94 crore as of 31 March 2021. Intangible assets declined from Rs 37.13 crore to Rs 34.68 crore.
Profit before tax grew 36.56% to Rs 73.17 crore. Provision for tax was expense of Rs 21.69 crore, compared to Rs 13.58 crore. Effective tax rate was 29.64% compared to 25.35%.
Profit after tax rose 28.70% to Rs 51.48 crore.
Promoters’ stake was 72.07% as of 31 March 2022 ,compared to 72.07% as of 31 March 2021 .
Cash flow from operating activities increased to Rs 64.75 crore for year ended March 2022 from Rs 58.27 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 23.95 crore, compared to Rs 8.51 crore during the year ended March 2021.
Management Comments :
Mr. Yugal Sikri, Managing Director, RPG
Life Sciences said, “In Q1 FY23, the overall performance of the Company
continued to be strong despite the geo-political challenges impacting supply
chain and costs. Revenue and PBT grew by 19% and 30% respectively Y-o-Y. EBITDA
margin retained its upward trajectory growing from 21.6% to 22.5% Y-o-Y.
Domestic Formulations business has recorded a robust growth both in value and
volumes - significantly and consistently better than the market. While our
comprehensive life cycle management program for legacy brands is helping them
register healthy growth, our new product portfolio comprising of newer and
progressive segments is also witnessing an impressive uptake. We have
successfully forayed into a new therapy area - Rheumatology, which is
strengthening our Specialty segment. Salesforce productivity continues to
register healthy upward momentum. International Formulations business has shown
a robust recovery while API business continue to register growth. Our unique
digital initiative, RPGServ, is having impressive traction in physician connect
and engagement. Going forward, we stay committed to implementing our
Transformation Agenda to grow both topline and bottomline across segments.”